非转移性肌层浸润性膀胱癌的新辅助顺铂为基础化疗:系统综述与汇总Meta分析以确定首选方案
该系统综述与Meta分析比较新辅助剂量密集甲氨蝶呤、长春碱、多柔比星和顺铂(ddMVAC)与吉西他滨联合顺铂(GC)在根治性膀胱切除术前治疗肌层浸润性膀胱癌的疗效。共纳入10项研究,ddMVAC较GC改善总生存(HR 0.71,95%CI 0.56-0.90)、无进展生存(HR 0.76,95%CI 0.60-0.97)和病理降期(OR 1.34,95%CI 1.01-1.78),病理完全缓解率无显著差异(OR 1.38,95%CI 0.90-2.12),但ddMVAC毒性更大。作者认为能耐受其更大毒性的患者应优先选择ddMVAC。
要点
- 与GC相比,新辅助ddMVAC改善肌层浸润性膀胱癌患者的总生存(HR 0.71,95%CI 0.56-0.90)。
- ddMVAC较GC改善无进展生存(HR 0.76,95%CI 0.60-0.97)和病理降期(OR 1.34,95%CI 1.01-1.78)。
- 两方案病理完全缓解率无显著差异(OR 1.38,95%CI 0.90-2.12),ddMVAC毒性更大。
核心结论
- 对于肌层浸润性膀胱癌根治性膀胱切除术前患者,新辅助ddMVAC较吉西他滨联合顺铂与改善的总生存和无进展生存相关。
- 虽然病理完全缓解率无显著差异,但病理降期与总生存相关。
- 作者认为,对于能耐受ddMVAC更大毒性的肌层浸润性膀胱癌患者,应优先选择ddMVAC而非吉西他滨联合顺铂。
研究设计与样本
- 系统综述与汇总Meta分析,检索PubMed、Web of Science和EMBASE数据库中比较新辅助GC与ddMVAC治疗肌层浸润性膀胱癌的研究。
- 共纳入10项研究,其中4项报告总生存、2项报告无进展生存、6项报告病理完全缓解临床终点。
- 总生存和无进展生存采用随机效应模型汇总对数转换风险比(通用逆方差法),病理完全缓解和降期采用Mantel-Haenszel法汇总比值比。
主要发现
- 与GC相比,新辅助ddMVAC改善总生存(HR 0.71,95%CI 0.56-0.90)。
- 与GC相比,新辅助ddMVAC改善无进展生存(HR 0.76,95%CI 0.60-0.97)。
- 与GC相比,新辅助ddMVAC改善病理降期(OR 1.34,95%CI 1.01-1.78)。
- 两方案病理完全缓解率无显著差异(OR 1.38,95%CI 0.90-2.12)。
- ddMVAC的治疗毒性大于GC。
关键数值与推荐
- 新辅助ddMVAC对比GC的总生存HR 0.71(95%CI 0.56-0.90)。
- 新辅助ddMVAC对比GC的无进展生存HR 0.76(95%CI 0.60-0.97)。
- 新辅助ddMVAC对比GC的病理降期OR 1.34(95%CI 1.01-1.78)。
- 新辅助ddMVAC对比GC的病理完全缓解OR 1.38(95%CI 0.90-2.12),无显著差异。
临床怎么用
- 作者认为,对于能耐受ddMVAC更大毒性的肌层浸润性膀胱癌患者,应优先选择ddMVAC而非吉西他滨联合顺铂。
- ddMVAC治疗毒性大于GC。
局限性
- 局限性源于研究间ddMVAC周期数和患者选择存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether neoadjuvant gemcitabine and cisplatin (GC) vs dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) before radical cystectomy improves overall survival (OS), progression-free survival (PFS), and pathologic complete response (pCR) for patients with muscle-invasive bladder cancer with secondary analyses of pathological downstaging and toxicity. MATERIALS AND METHODS: This systematic review and meta-analysis identified studies of patients with muscle-invasive bladder cancer treated with neoadjuvant GC compared to ddMVAC from PubMed, Web of Science, and EMBASE. Random-effect models for pooled log-transformed hazard ratios (HR) for OS and PFS and pooled odds ratios for pCR and downstaging were developed using the generic inverse variance method and Mantel-Haenszel method, respectively. RESULTS: Ten studies were identified (4 OS, 2 PFS, and 6 pCR clinical endpoints). Neoadjuvant ddMVAC improved OS (HR 0.71 [95% confidence intervals 0.56; 0.90]), PFS (HR 0.76 [95% confidence intervals 0.60; 0.97]), and pathological downstaging (odds ratio 1.34 [95% confidence interval 1.01; 1.78]) as compared to GC. There was no significant difference between regimens for pCR rates (odds ratio 1.38 [95% confidence interval 0.90; 2.12]). Treatment toxicity was greater with ddMVAC. Limitations result from differences in number of ddMVAC cycles and patient selection between studies. CONCLUSION: Neoadjuvant ddMVAC is associated with improved OS and PFS vs gemcitabine/cisplatin for patients with muscle-invasive bladder cancer before radical cystectomy. Although rates of pathological complete response were not significantly different, pathological downstaging correlated with OS. ddMVAC should be preferred over gemcitabine/cisplatin for patients with muscle-invasive bladder cancer who can tolerate its greater toxicity.
引用
- Eule CJ, Warren A, Molina Kuna E, et al. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen. Urology. 2024. PMID: 38685388. doi:10.1016/j.urology.2024.04.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。